

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GOLDEN MEDITECH HOLDINGS LIMITED

金衛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00801)

ANNOUNCEMENT MADE PURSUANT TO RULES 13.51(2)(U) AND 13.51B(2) OF THE LISTING RULES

This announcement is made by Golden Meditech Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51(2)(u) and 13.51B(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) in relation to Mr. Poon Tsz Hang (“**Mr. Poon**”), an independent non-executive director of the Company.

The board of directors of the Company (the “**Board**”) has been recently informed by Mr. Poon that Mr. Poon has been named as one of the respondents in a petition dated 9 September 2019 (the “**Petition**”) filed in the Court of First Instance of the High Court of Hong Kong by the Securities and Futures Commission of Hong Kong (the “**SFC**”) pursuant to section 214 of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”) in the matter of a company the shares of which were delisted from The Stock Exchange of Hong Kong Limited in November 2017 (the “**Delisted Company**”). The Petition is in respect of the business or affairs of the Delisted Company during the period from 2007 to 2014, which the SFC alleges to have been conducted in a manner as described in sections 214(1)(b), (c) and (d) of the SFO. Mr. Poon was the Senior Financial Manager, the Financial Controller and the Company Secretary of the Delisted Company from December 2007 to March 2014.

The Board has been informed by Mr. Poon that he intends to contest the Petition vigorously.

Being an independent non-executive director of the Company, Mr. Poon is not involved in day-to-day operations of the Company. The Board believes that the Petition will not have any material adverse impact on the business operation of the Group. As at the date of this announcement, the business of the Group is operating as usual.

Further announcement(s) will be made by the Company as and when appropriate.

By order of the Board
Golden Meditech Holdings Limited
Feng Wen
Chairman

Hong Kong, 20 September 2019

As at the date of this announcement, the Board comprises five directors. The executive directors are Mr. Feng Wen (Chairman) and Mr. Leong Kim Chuan (Chief executive); and the independent non-executive directors are Mr. Gao Yue, Mr. Poon Tsz Hang and Mr. Daniel Foa.